The Outlook for Biomanufacturing Capacity

As the number of biologic-based drugs in development and commercialization grows, a crucial issue for the industry is the availability of biomanufacturing capacity. So where does the industry stand?.

At DCAT Week ‘16, being held March 14-17 in New York, the education program, Biopharmaceutical Forum: Global Biomanufacturing Trends, Capacity, and Technology Drivers, will address this issue with insight on the major capacity additions by pharmaceutical and biopharmaceutical companies and contract manufacturing organizations (CMOs) and the impact on supply-demand fundamentals for biomanufacturing capacity.

Examining the issue 
The program, Biopharmaceutical Forum: Global Biomanufacturing Trends, Capacity, and Technology Drivers, scheduled for Wednesday March 16 from 2:00 to 4:30 PM at the Waldorf Astoria in New York, will examine a crucial issue for the industry: will there be sufficient biomanufacturing capacity to accommodate growing biologic-based drug development and commercialization both currently and in the near-term and what is the mix between microbial and mammalian cell culture capacity? The program will also examine the specialized issues in developing and managing the supply lines for biologic-based drugs. 

Addressing these issues will be two well-respected consultants that will provide the market numbers, expansion activity, as well as technology drivers impacting biomanufacturing. Patricia Seymour, Senior Consultant, BioProcess Technology Consultants, Inc, will provide an industry overview of biomanufacturing to examine current and projected industry capacity utilization, expansion activity among pharmaceutical and biopharmaceutical companies, and the key technology advances impacting supply and demand biomanufacturing fundamentals. William Downey, President, High Tech Business Decisions, will provide an-depth analysis of the contract biomanufacturing market, outsourcing trends for biologic-based drug substances, CMO capacity utilization, technology differentiation impacting supplier strategies, and the production economics influencing make–buy decisions.

The program will also provide perspectives from leading pharmaceutical companies on issues impacting biologic-based supply strategies and the role of external partners in filling supply needs, including perspectives on key operational issues and the integration of internal and external supply networks, best practices in sourcing and procurement for biologics, and key considerations in supplier risk management for biologics. These issues will be addressed in presentations and a panel discussion with: Mike Cicio, Vice President, Commercial Recombinant Manufacturing, Baxalta; Bruce Smith, Associate Director, Sourcing & Procurement,AstraZeneca; and Chris Calabretta, Global Procurement Leader, Direct Materials Biologics & Vaccines, Janssen Pharmaceuticals.

Further information, including how to register, may be found here. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.

The CDMO/CMO and Suppliers Report: Biomanufacturing

By
Driven by increased demand in biologic-based drugs, biomanufacturing (biologic drug substance) continues to be an active area of investment by CDMOs/CMOs, including several multi-billion large-scale biomanufacturing projects. What companies are expanding and where do these expansions stand?

Drug Shortages on the Rise; US Gov’t Proposes New Actions to Address

By
The number of drug shortages in the US has reached a new all-time high, with more than 320 drugs in shortage, according to an analysis by a pharmacist trade group. Earlier this month, the White House proposed new actions to address the problem, including additional requirements for manufacturers.